Sign in

Private company

ALBIREO PHARMA, INC.

American pharmaceutical preparations company based in Boston, active since 20032

In its 2022 annual report the company says: “We are a commercial-stage biopharmaceutical company focused on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Our product Bylvay has been approved in the United States for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis (PFIC) ages 3 months or older, and authorized in Europe for the treatment of PFIC in patients ages 6 months or older.”89

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersBoston, United States2
  • Incorporated inDE3
  • Business address10 Post Office Square, Suite 502 South, Boston, Ma 021093
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300835H8LC7O8VC292
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 37366312

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

96.7%Gross margin4
-304.3%Operating margin4
-83.9%Net margin4
388.4%Revenue growth, 20214
-19.4%Return on equity4
-$108.0MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Cost of revenue1¢$1.4M
  • Research and development54¢$82.5M
  • Selling, general and admin45¢$69.6M

Out of $40.6M in revenue.4 The company lost money this year.

Financial statements

Revenue567894$40.6M in 2021+696% since 2015
0$20.0M$40.0M$60.0M2015: $5.1M$5.1M20152016: $11.4M$11.4M2016+123%2017: $1.0K$1.0K2017−100%2018: $12.7M$12.7M2018+1273900%2019: $9.6M$9.6M2019−24%2020: $8.3M$8.3M2020−14%2021: $40.6M$40.6M2021+388%
Gross profit4$39.2M in 2021+372% since 2020
0$10.0M$20.0M$30.0M$40.0M2020: $8.3M$8.3M20202021: $39.2M$39.2M2021+372%
Operating income567894-$123.5M in 2021+2513% since 2015
-$150.0M-$100.0M-$50.0M02015: -$4.7M-$4.7M20152016: -$12.3M-$12.3M2016+160%2017: -$24.6M-$24.6M2017+100%2018: -$37.9M-$37.9M2018+54%2019: -$61.1M-$61.1M2019+61%2020: -$96.3M-$96.3M2020+58%2021: -$123.5M-$123.5M2021+28%
Net income567894-$34.0M in 2021+403% since 2015
-$150.0M-$100.0M-$50.0M02015: -$6.8M-$6.8M20152016: -$16.4M-$16.4M2016+142%2017: -$24.4M-$24.4M2017+49%2018: -$46.1M-$46.1M2018+89%2019: -$62.7M-$62.7M2019+36%2020: -$107.6M-$107.6M2020+72%2021: -$34.0M-$34.0M2021−68%
Fiscal year2015201620172018201920202021
Revenue$5.1M5$11.4M6$1.0K7$12.7M8$9.6M9$8.3M4$40.6M4
Cost of revenue$1.4M4
Gross profit$8.3M4$39.2M4
Research and development$5.6M5$8.1M6$13.0M7$31.7M8$45.6M9$76.8M4$82.5M4
Selling, general and admin$42.4M4$69.6M4
Operating expenses$162.7M4
Operating income-$4.7M5-$12.3M6-$24.6M7-$37.9M8-$61.1M9-$96.3M4-$123.5M4
Income before tax-$34.0M4
Income tax$05$62.0K6$212.0K7$20.0K8
Net income-$6.8M5-$16.4M6-$24.4M7-$46.1M8-$62.7M9-$107.6M4-$34.0M4
Earnings per share-$6.734-$1.774
Earnings per share (diluted)-$6.734-$1.774
Shares (weighted, basic)19.2M shares4
Shares (weighted, diluted)19.2M shares4

Compare ALBIREO PHARMA, INC. with another company

Corporate structure

ALBIREO PHARMA, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of ALBIREO PHARMA, INC.

  • ALBIREO PHARMA, INC. Boston, Massachusetts, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What ALBIREO PHARMA, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.3M4 Dec 31, 2021$829.0K4 Dec 31, 2020+54.5%
Accumulated depreciation$613.0K4 Dec 31, 2021$351.0K4 Dec 31, 2020+74.6%
Property and equipment, net$668.0K4 Dec 31, 2021$478.0K4 Dec 31, 2020+39.7%
Operating-lease assets (leased space)$12.0M4 Dec 31, 2021$4.1M9 Dec 31, 2020+192.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$248.1M4 Dec 31, 2021$251.3M4 Dec 31, 2020−1.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$17.3M4 Dec 31, 2021$17.3M4 Dec 31, 20200%

Inventory

ItemLatestA year beforeChange
Inventory, total$194.0K4 Dec 31, 2021
Finished goods$194.0K4 Dec 31, 2021

Leadership

Who has led ALBIREO PHARMA, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Solomon Steiner2007–2009
  2. Errol B. Desouza2010–2015
  3. Ronald Harold Wilfred Cooper2016–2023

President

  1. Solomon Steiner2007–2009
  2. Erik Steiner2007–2013
  3. Errol B. Desouza2010
  4. Ronald Harold Wilfred Cooper2016–2023

Chief financial officer

  1. F. Scott Reding2007
  2. Gerard J. Michel2007–2014
  3. Gary G. Gemignani2014–2016
  4. Simon N.r. Harford2018–2023

Chief operating officer

  1. Jan Mattsson2016–2020
2010201520202025
Board members and other officers (44)

Former names

  • Biodel IncMar 28, 2005 to Nov 2, 20163

Timeline

  1. Mar 2, 20238-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights63
  2. Feb 14, 20238-K Other events64
  3. Jan 9, 20238-K Entered a material agreement; Regulation FD disclosure65
  4. Dec 6, 20228-K Executive or director change; Regulation FD disclosure66
  5. Nov 8, 20228-K Results of operations67
  6. Oct 11, 20228-K Results of operations; Other events68
  7. Sep 22, 20228-K Entered a material agreement; Regulation FD disclosure69
  8. Aug 22, 20228-K Executive or director change70
  9. Aug 16, 20228-K Entered a material agreement; Ended a material agreement71
  10. Aug 15, 20228-K Results of operations72
  11. Aug 10, 20228-K Executive or director change; Regulation FD disclosure73
  12. Jul 29, 20228-K Ended a material agreement74
  13. Nov 7, 2016New chief executive Ronald Harold Wilfred Cooper becomes CEO13
  14. Apr 2, 2010New chief executive Errol B. Desouza becomes CEO14
  15. May 10, 2007New chief executive Solomon Steiner becomes CEO15
  16. Dec 8, 2003Founded ALBIREO PHARMA, INC. is founded2

Calendar

When it reported results

  1. Nov 8, 2022Reported quarterly or annual results67
  2. Oct 11, 2022Reported quarterly or annual results68
  3. Aug 15, 2022Reported quarterly or annual results72
  4. May 16, 2022Reported quarterly or annual results75
  5. Mar 1, 2022Reported quarterly or annual results76
  6. Jan 5, 2022Reported quarterly or annual results77
  7. Nov 4, 2021Reported quarterly or annual results78

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

192 filings to the SEC since October 2021: 1 annual reports, 4 quarterly reports, 19 major events, 107 insider forms, 20 large holders, 41 other. The latest 20:

  1. Feb 14, 2024SC 13G/A EDGAR
  2. Apr 10, 2023SC 13G/A EDGAR
  3. Mar 14, 202315-12G EDGAR
  4. Mar 8, 2023EFFECT EDGAR
  5. Mar 8, 2023EFFECT EDGAR
  6. Mar 8, 2023EFFECT EDGAR
  7. Mar 8, 2023EFFECT EDGAR
  8. Mar 8, 2023EFFECT EDGAR
  9. Mar 8, 2023SC 13G/A EDGAR
  10. Mar 3, 20234 FORM 4 SUBMISSION EDGAR
  11. Mar 2, 2023SC 13G EDGAR
  12. Mar 2, 202325-NSE EDGAR
  13. Mar 2, 20234 FORM 4 SUBMISSION EDGAR
  14. Mar 2, 20234 FORM 4 SUBMISSION EDGAR
  15. Mar 2, 20234 FORM 4 SUBMISSION EDGAR
  16. Mar 2, 20234 FORM 4 SUBMISSION EDGAR
  17. Mar 2, 20234 FORM 4 SUBMISSION EDGAR
  18. Mar 2, 20234 FORM 4 SUBMISSION EDGAR
  19. Mar 2, 20234 FORM 4 SUBMISSION EDGAR
  20. Mar 2, 20234 FORM 4 SUBMISSION EDGAR

The 192 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

62 open-market trades by officers, directors and large owners since October 2021: 0 buys and 62 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jan 23, 2023Stephenson PamelaChief Commercial OfficerSale102$43.80$4.5KForm 4
Jan 23, 2023Graham MichelleChief Human Resources OfficerSale102$43.80$4.5KForm 4
Jan 23, 2023Mattsson JanChief Scientific OfficerSale197$43.80$8.6KForm 4
Jan 23, 2023Harford Simon N.R.CFO and TreasurerSale102$43.80$4.5KForm 4
Jan 23, 2023Duncan JasonChief Legal Officer and GCSale228$43.80$10.0KForm 4
Jan 23, 2023Cooper Ronald Harold WilfredPresident and CEOSale1,057$43.80$46.3KForm 4
Jan 23, 2023Carter Martha J.Chief Regulatory OfficerSale120$43.80$5.3KForm 4
Jan 19, 2023Stephenson PamelaChief Commercial OfficerSale1,774$43.90$77.9KForm 4
Jan 19, 2023Carter Martha J.Chief Regulatory OfficerSale938$43.90$41.2KForm 4
Jan 19, 2023Duncan JasonChief Legal Officer and GCSale938$43.90$41.2KForm 4
Jan 19, 2023Mattsson JanChief Scientific OfficerSale3,088$43.80$135.3KForm 4
Jan 19, 2023Graham MichelleChief Human Resources OfficerSale1,774$43.90$77.9KForm 4
Jan 19, 2023Harford Simon N.R.CFO and TreasurerSale1,776$43.80$77.8KForm 4
Dec 27, 2022Stephenson PamelaChief Commercial OfficerSale469$19.06$8.9KForm 4
Dec 27, 2022Stephenson PamelaChief Commercial OfficerSale469$19.06$8.9KForm 4
Oct 24, 2022Cooper Ronald Harold WilfredPresident and CEOSale919$19.58$18.0KForm 4
Oct 24, 2022Stephenson PamelaChief Commercial OfficerSale104$19.58$2.0KForm 4
Oct 24, 2022Duncan JasonChief Legal Officer and GCSale656$19.45$12.8KForm 4
Oct 24, 2022Mattsson JanChief Scientific OfficerSale202$19.58$4.0KForm 4
Oct 24, 2022Graham MichelleChief Human Resources OfficerSale104$19.58$2.0KForm 4

All 62 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How ALBIREO PHARMA, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARALBIREO PHARMA, INC.1
  • CIK0001322505
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address10 Post Office Square, Suite 502 South, Boston, MA 021091
  • Phone857-415-47741
  • Shares outstanding20,701,283 as of Nov 1, 202211
  • Public float$672.7M as of Jun 30, 20214
  • On EDGAR sinceMar 28, 20051
  • Filings1,239 in all: 4 (551), 8-K (199), SC 13G/A (65), 3 (59), 10-Q (47), SC 13G (39), 4/A (25), CORRESP (20)1
    All 54 form types

    EFFECT (18), UPLOAD (18), DEFA14A (17), 10-K (16), DEF 14A (15), 424B5 (13), CT ORDER (10), S-8 (10), S-8 POS (10), SC 13D/A (10), S-3 (9), SC 13D (8), 8-K/A (7), S-1/A (6), 3/A (5), 424B3 (5), POS AM (5), PRE 14A (5), S-1 (4), 10-Q/A (3), 425 (3), ARS (3), SC 14D9/A (3), 424B4 (2), FWP (2), PRER14A (2), REGDEX (2), S-3/A (2), SC TO-C (2), SC TO-T/A (2), SC14D9C (2), 10-K/A (1), 15-12G (1), 25-NSE (1), 424B1 (1), 8-A12B (1), CERTNAS (1), D (1), DEFM14A (1), DEFR14A (1), NT 10-K (1), NT 10-Q (1), PREM14A (1), S-3ASR (1), SC 14D9 (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Mar 1, 2022
    Quarterly report (10-Q) Nov 8, 2022
    Proxy statement (DEF 14A) Apr 21, 2022
    Latest 8-K (8-K) Mar 2, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
    SEC EDGAROther events
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89